Skip to main content
Equibles
NPCE logo

NPCE · NeuroPace Inc

Track NPCE — free

Use NPCE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NPCE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.04 +0.02 (+0.14%) At close · Aug 21
Market Cap
$481.57M
Shares
34.32M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.02 Open$14.35 Day$13.56–14.60 52W close$8.62–19.29 Avg vol 30d210K Short int822K · 2.4% float · 3.9d Short vol79% Last earningsAug 11, 2026 DataApr 2021–Aug 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 7, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 16 · calm Equity put/call 0.58
      Technical
      price trend
      Neutral
      50 / 200-day cross Death cross
      Price vs 200-day avg −9%
      below
      Price vs 50-day avg −9%
      below
      RSI (14) 43
      neutral
      MACD trend Positive
      52-week position 51%
      mid-range
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Very Weak
      1-month return −5%
      trailing
      6-month return −4%
      trailing
      YTD return −9%
      this year
      Relative strength −15%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Death cross
      50d $15 › 200d $15 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +19 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.40% of float · ▼ -6.0% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      112 holders — near 3-yr high, broad support
      Squeeze score 40
      low risk · 0–100
      Fundamentals
      Strong
      Revenue growth +25%
      Y/Y
      Gross margin 77%
      expanding
      EPS growth +29%
      Y/Y
      Free cash flow $-11.3M
      Balance sheet $37.2M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 63%
      annualized · 1-yr
      Max drawdown −33%
      past year
      ATR 5.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Aug 11, 2026
      Total revenue · full year 2026 Initiated $99.5M – $101.5M
      prior FY $99.99M midpoint +0.5% Y/Y
      Non-GAAP gross margin · full year 2026 Non-GAAP Initiated 82% – 83%
      Non-GAAP operating expenses · full year 2026 Non-GAAP Initiated $90M – $92M
      Adjusted EBITDA · full year 2026 Non-GAAP Initiated $-8.5M – $-7.5M
      Prior guidance period ended · from the 8-K filed Mar 3, 2026
      Total revenue · first quarter 2026 $21M – $22M
      Guided vs delivered · last 3 settled
      Total revenue full year 2025
      guided $97M – $98M
      $99.99M Beat +2.5%
      Revenue full year 2024
      guided $73M – $77M
      $79.91M Beat +6.5%
      Full year 2023 revenue full year 2023
      guided $62.5M – $63.5M
      $65.42M Beat +3.8%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      3 · 2 · 2
      50 / 200-day cross
      Death cross Bearish
      Price vs 200-day avg
      −9% Bearish
      Price vs 50-day avg
      −9% Bearish
      RSI (14)
      43 Neutral
      MACD trend
      Positive Bullish
      52-week position
      51% Neutral
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) Death cross
      50d $15 › 200d $15 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +19 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.40% of float · ▼ -6.0% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      112 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $9 Now $14 · 51% Range high $19
      vs 200-day avg -9% vs 50-day avg -9% 50-day below 200-day death cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA from continuing operations (Non-GAAP) non-GAAP -6.04M Six Months Ended June 30, 2026 —
      Adjusted EBITDA loss non-GAAP -$2.8M second quarter of 2026 —
      Non-GAAP general and administrative expense non-GAAP $4.1M second quarter of 2026 —
      Non-GAAP gross margin non-GAAP 83.4% second quarter of 2026 —
      Non-GAAP loss from operations non-GAAP -$2.8M second quarter of 2026 —
      Non-GAAP net loss non-GAAP -$3.9M second quarter of 2026 —
      Non-GAAP operating expenses non-GAAP $21.9M second quarter of 2026 —
      Non-GAAP research and development expense non-GAAP $6.3M second quarter of 2026 —
      Non-GAAP sales and marketing expense non-GAAP $11.5M second quarter of 2026 —
      Adjusted EBITDA (Non-GAAP) (excluding DIXI) non-GAAP -$3.27M Three Months Ended March 31, 2026 —
      Adjusted EBITDA non-GAAP $0.9M the fourth quarter of 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NPCE
      NeuroPace Inc
      this stock
      		$481.57M -9.2% +25.1% — 2.4%
      ABT
      Abbott Laboratories
      		 $198.81B -8.9% +5.7% 32.0 1.3%
      SYK
      Stryker Corp
      		 $127.26B -6.8% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $119.47B -3.9% +8.4% 25.0 1.4%
      BSX
      Boston Scientific Corp
      		 $71.55B -48.2% +12.5% 20.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      112
      % held
      77.4%
      Net QoQ
      +108.0K sh
      Top holder
      Polar Capital Holdings Plc
      Held Float
      View
      Held by Funds
      Fund positions
      112
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      822.1K
      Days to cover
      3.9d
      Change
      -52.2K sh
      View
      Short Volume
      Short vol %
      79%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      857
      Value
      $14.7K
      As of
      Jul 13, 2026
      View
      Off-Exchange
      Off-exchange %
      43.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $100.0M
      Net income (FY)
      $-21.5M
      EPS diluted
      $-0.66
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 11, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $404.8K
      Shares
      25.0K
      Filed
      Dec 15, 2025
      View
      Exempt Offerings
      Offering
      $96.4M
      Filed
      Aug 31, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View
      Investor Relations
      Latest news
      NeuroPace Reports Second Quarter…
      Published
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NPCE -3.4% -4.5% -3.8% +8.8% -9.2%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -1.4% -7.8% -15.0% +6.7% -21.0%
      Key facts CIK 1528287 CUSIP 641288105 13F (30d) 107 filings 106 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)